

E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

Pharmacovigilance of Vonoprazan: A Review of Safety and Adverse Event Profiles

Mr. Tejas Vinod Fendar¹, Mr. Dipak Vasant Pawar², Miss. Tejaswini Mahadev Ghorpade³, Mr. Prem Dilip Fendar⁴, Miss Gayatri Vilas Jadhao⁵, Mr. Dhiraj D. Mangam⁶, Dr. Avinash S. Jiddewar⁷

^{1,2}Bachelor of Pharmacy, Science, Nspm college of Pharmacy
 ^{3,4,5}Bachelor of Pharmacy, Science
 ⁶M Pharm, Quality Assurance
 ⁷Principle, Pharmacology, Nspm College of Pharmacy

ABSTRACT

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and Helicobacter pylori eradication therapy. Compared to traditional proton pump inhibitors (PPIs), vonoprazan exhibits a faster onset of action and sustained acid suppression. This pharmacovigilance review evaluates its safety profile based on post-marketing surveillance and clinical studies.

Data from the Japanese Adverse Drug Event Report (JADER) database and systematic reviews indicate that vonoprazan has a generally comparable safety profile to PPIs. Common adverse events include diarrhea, liver function abnormalities, and rash. However, vonoprazan has been associated with an increased risk of hemorrhagic enterocolitis, necessitating further investigation. Unlike PPIs, it does not show a significant correlation with interstitial lung disease. Meta-analyses suggest no significant increase in overall adverse events compared to PPIs, with some studies reporting fewer gastrointestinal side effects. Despite its favorable tolerability, long-term safety data remain limited. Continuous pharmacovigilance efforts and real-world studies are crucial to identifying rare but serious adverse effects. Future research should focus on elucidating the mechanisms underlying vonoprazan-associated risks and optimizing its safe clinical use.

Keywords: Vonoprazan, Pharmacovigilance, Adverse Drug Reactions, Potassium-Competitive Acid Blocker, Proton Pump Inhibitors, Gastroesophagel Reflux Disease

1. INTRODUCTION:

Vonoprazan is a potassium-competitive acid blocker which, unlike conventional PPIs, reversibly inhibits the enzyme H+/K+ ATPase independently of acid $pH^{1,2}$. In Japan, vonoprazan was marketed in 2015 for the treatment of erosive oesophagitis, treatment of gastric and duodenal ulcers, eradication of Helicobacter pylori, and prevention of the recurrence of low-dose aspirin or nonsteroidal anti-inflammatory drug-related gastric and duodenal ulcer³. To efficacy and safety of vonoprazan have been demonstrated in patients with erosive oesophagitis⁴, and also when administered as maintenance treatment in patients with healed



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

erosive oesophagitis refractory to conventional PPIs⁵. Furthermore, vonoprazan has demonstrated noninferiority to the conventional PPI lansoprazole in patients with erosive oesophagitis⁶. Since long-term maintenance treatment is recommended for patients with erosive oesophagitis⁷, it is imperative to establish the long-term safety of the therapeutic agent. As vonoprazan has been shown to have a more potent acid inhibitory effect than conventional PPIs both in vivo and in vitro⁸, greater concern has been raised about side effects than with conventional PPIs⁹. A number of side effects have been reported with strong inhibitors of gastric acid secretion, including PPIs, but the most problematic is their potential association with

neoplastic lesions such as gastric cancer and gastric neuroendocrine tumours (NET). ⁹the strong inhibition of gastric acid secretion causes hypergastrinemia, and gastrin is known to have a proliferative effect on the mucosa of the digestive tract ¹⁰, including the gastric mucosa¹¹. Findings from several observational studies suggest that long-term use of PPIs is associated with an increased risk of developing gastric cancer¹²; therefore, additional well-designed prospective studies are warranted to confirm the potential role of PPIs in gastric cancer development according to gastric histology at baseline¹³. Vonoprazan is a potent inhibitor of gastric acid secretion, resulting in increased gastrin levels compared with conventional PPIs. Hypergastrinemia is thought to be one of the pathogenic causes of hyperplastic polyps¹⁴, but there have been no prospective studies of vonoprazan-induced hypergastrinemia. In addition, endoscopic findings show that long-term treatment with PPIs is associated with a high incidence of lesions such as fundic gland polyps¹⁵, hyperplastic polyps¹⁶, cobblestone mucosa¹⁷, multiple white fat elevated lesions¹⁸, and black spots¹⁹. Although the safety and efficacy of vonoprazan as maintenance therapy have been previously reported in a 52-week study⁸, studies that examine the longer-term safety of vonoprazan maintenance treatment are needed. the objective of the Vonoprazan study In patients with erosive oesophagitis to evaluate long-term safety (VISION) is to evaluate the long-term safety and efficacy of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment for recurrent/reactivated erosive oesophagitis, compared with lansoprazole. Patients in the ongoing VISION trial will receive treatment for up to 5 years, but as vonoprazan is being used more frequently in clinical practice, we are reporting the results of the prespecified 3-year interim analysis to provide information on the long-term safety of vonoprazan that may be of reassurance to practitioners. the objective of the Vonoprazan study In patients with erosive oesophagitis to evaluate long-term safety (VISION) is to evaluate the long-term safety and efcacy of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment for recurrent/reactivated erosive oesophagitis, compared with lansoprazole. Patients in the ongoing VISION trial will receive treatment for up to 5 years, but as vonoprazan is being used more frequently in clinical practice, we are reporting the results of the prespecifed 3-year interim analysis to provide information on the long-term safety of vonoprazan that may be of reassurance to practitioners.

Proton pump inhibitors (PPIs) have often been used for acid related diseases including gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, non-steroidal anti-inflammatory drug (NSAID)-associated ulcers, and Helicobacter pylori eradication therapy. Conventional PPIs with a benzimidazole structure irreversibly inhibit hydrogen potassium (H+, K+)-ATPases, which produce acid in gastric parietal cells and more strongly block acid secretion compared to histamine H2 receptor antagonists.²⁰Although PPIs have been used for more than a quarter-century as a first-line treatment for these diseases, it has become clear that there are some issues in need of improvement (Table 1).²¹ First, it takes several days to show maximal effect.²²Reflux symptoms of GERD are not sufficiently relieved after the first dose of PPIs in two-thirds of patients because of its slow onset of the action,²³ and one-half of



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

patients still have symptoms even after 3 days of treatment.²³ Second, the effects of PPIs are influenced by cytochrome P450 (CYP) 2C19 polymorphism.²⁴ Third, its effects at night are not satisfactory.²⁵Finally, although it requires an acidic environment for activation, PPIs are unstable in acidic conditions,²⁶ so enteric coating is needed

To overcome the aforementioned unmet needs, alternative formulations of conventional PPIs and new H+, K+-ATPase inhibitors have been established. With these efforts, vonoprazan (TAK-438), a potassium-competitive acid blocker (P-CAB), was developed. It was found to have satisfactory effects and a good safety profile in clinical studies of gastric and duodenal ulcers, reflux esophagitis, NSAID-associated ulcers, and H. pylori eradication. Vonoprazan (Takecab) was released to the market in Japan in February 2015. In this review, we summarize the effects of P-CABs, mainly using vonoprazan data. Alternative Formulation of Conventional Proton Pump Inhibitors Immediate-release omeprazole and dexlansoprazole modified release (MR), which improve nocturnal acid breakthrough (NAB), have been introduced as alternative formulations of PPIs in some countries.²⁷Dexlansoprazole MR is the R-enantiomer of lanso prazole and is a PPI with dual delayed-release formulation.18 The dual release system in the duodenum and small intestine achieved 2 peak concentrations within 2 hours and 5 hours after administration.²⁹ Percentage time 24-hour intragastric pH above 4 of dexlansoprazole MR 60 mg and lansoprazole 30 mg once daily for 5 days administration was 71% and 60%, respectively (P < 0.01).20 However, these drugs only have small advantages for the control of acid secretion compared to conventional PPIs.²⁸

1.2 WHY IS PHARMACOVIGILANCE IMPORTANT?

Pharmacovigilance is critically important, especially when evaluating drugs like Vonoprazan, a relatively new potassium-competitive acid blocker (P-CAB), because it ensures the ongoing monitoring of drug safety after it has been approved for use.

- 1. Ensures Patient Safety
- 2. Detects Rare and Delayed Adverse Events
- 3. Monitors Drug Interactions and Off-label Use
- 4. Improves Clinical Guidelines
- 5. Supports Regulatory Actions

1.3 BRIEF OVERVIEW OF ADVERSE EVENTS

AEs were reported in 89.6% of patients in the vonoprazan group and 95.5% of patients in the lansoprazole group (Table 1). AEs were mostly mild or moderate in severity, and the majority of AEs were not considered to be related to the vonoprazan or lansoprazole. During the maintenance phase up to week 156, 10 patients (7.4%) in the vonoprazan group and none in the lansoprazole group discontinued treatment because of an AE. No deaths were reported. The most commonly reported AEs, occurring in>5% of the study population, were in the system organ classes 'gastrointestinal disorders' and 'infections and infestation³⁰

TEAEs	VPZ (N = 135)	LPZ (N = 67)
Overview of TEAEs, n (%)		
All TEAEs	121 (89.6%)	64 (95.5%)
Related to study drug	54 (40.0%)	31 (46.3%)
Serious TEAEs	39 (28.9%)	18 (26.9%)
- Related to study drug	3 (2.2%)	0 (0.0%)

 Table 1: Overview of TEAEs in the Maintenance Phase up to Week 156



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • En

• Email: editor@ijfmr.com

TEAEs occurring in >5% of patients in any group, n (%)Gastrointestinal disorders84- Gastric polyps48- Gastric mucosal lesion21- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((0.0%) (62.2%) (35.6%) (15.6%) (8.1%) (9.6%) (6.7%) (4.4%) (5.2%)	0 (0.0%) 54 (80.6%) 27 (40.3%) 11 (16.4%) 8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%) 2 (3.0%)
patients in any group, n (%)Gastrointestinal disorders84- Gastric polyps48- Gastric mucosal lesion21- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((35.6%) (15.6%) (8.1%) (9.6%) (6.7%) (4.4%)	27 (40.3%) 11 (16.4%) 8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%)
Gastrointestinal disorders84- Gastric polyps48- Gastric mucosal lesion21- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((35.6%) (15.6%) (8.1%) (9.6%) (6.7%) (4.4%)	27 (40.3%) 11 (16.4%) 8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%)
- Gastric polyps48- Gastric mucosal lesion21- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((35.6%) (15.6%) (8.1%) (9.6%) (6.7%) (4.4%)	27 (40.3%) 11 (16.4%) 8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%)
- Gastric mucosal lesion21- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((15.6%) (8.1%) (9.6%) (6.7%) (4.4%) (5.2%)	11 (16.4%) 8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%)
- Gastritis erosive11- Large intestine polyp13- Diarrhoea9 (- Gastrointestinal mucosal6 ((8.1%) (9.6%) (6.7%) (4.4%) (5.2%)	8 (11.9%) 9 (13.4%) 4 (6.0%) 6 (9.0%)
 - Large intestine polyp - Diarrhoea - Gastrointestinal mucosal - 6 (- 	(9.6%) (6.7%) (4.4%) (5.2%)	9 (13.4%) 4 (6.0%) 6 (9.0%)
- Diarrhoea9 (- Gastrointestinal mucosal6 ((6.7%) (4.4%) (5.2%)	4 (6.0%) 6 (9.0%)
- Gastrointestinal mucosal 6 ((4.4%)	6 (9.0%)
```````````````````````````````````````	(5.2%)	. ,
	, ,	2 (3.0%)
disorder	, ,	2 (3.0%)
- Constipation 7 (		- (0.070)
- Dyspepsia 2 (	(1.5%)	4 (6.0%)
Infections and infestations 80	(59.3%)	38 (56.7%)
- Nasopharyngitis 44	(32.6%)	26 (38.8%)
- Bronchitis 11	(8.1%)	7 (10.4%)
- Influenza 12	(8.9%)	1 (1.5%)
- Cystitis 8 (.	(5.9%)	2 (3.0%)
- Gastroenteritis 7 (.	(5.2%)	3 (4.5%)
- Pharyngitis 4 (	(3.0%)	5 (7.5%)
- Herpes zoster 2 (	(1.5%)	5 (7.5%)
- Tonsillitis 1 (	(0.7%)	4 (6.0%)
Musculoskeletal and 33	(24.4%)	16 (23.9%)
connective tissue disorders		
- Back pain 7 (.	(5.2%)	3 (4.5%)
Skin and subcutaneous 14	(10.4%)	14 (20.9%)
tissue disorders		
- Eczema 7 (.	(5.2%)	6 (9.0%)
Eye disorders 8 (.	(5.9%)	6 (9.0%)
- Cataract 2 (	(1.5%)	5 (7.5%)
Vascular and nervous		
system disorders		
-	(8.9%)	3 (4.5%)
- Dizziness 1 (	(0.7%)	4 (6.0%)

TEAE = treatment-emergent adverse event; LPZ = lansoprazole; VPZ = vonoprazan.

Among AEs with incidences of <5%, one case of gastric cancer, i.e., foveolar-type adenoma, was reported. Out of the 10 patients who discontinued due to an AE, the most common AEs were in the system organ classes gastrointestinal disorders', 'neoplasms benign, malignant and unspecifed (including cysts and polyps)' and 'infections and infestations.' The study drug was withdrawn in two patients because of treatment-related AEs. One patient experienced a mild treatment-related AE (gastric mucosal lesion) and a moderate serious AE (SAE) (acute cholangitis). After the SAE, the study drug was withdrawn in view of future interruptions in the study procedures. A second patient experienced two treatment-related SAEs



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

of mild intensity: abnormal hepatic function and leukopenia, and two mild SAEs not related to the treatment: tinnitus and loss of consciousness. Te

study drug was withdrawn due to the treatment-related SAEs and patient's anxiety regarding these SAEs. In the remaining eight patients, the study drug was withdrawn due to non-treatment related AEs. Te study drug was discontinued in four patients experiencing SAEs: suspected cancer of the tail of the pancreas in frst patient, duodenal obstruction because of uncinate pancreas cancer in the second patient, right lung cancer in the third patient, and myelodysplastic syndrome in the fourth patient. Study drug was also discontinued in two patients experiencing mild AEs: abnormal hepatic function in one and generalised pain in the second patient, and one

patient experiencing moderate AE of early colon cancer. In one patient the drug was withdrawn because of an SAE a malignant tumour – presumed to have existed before study participation (Table:2) and therefore this patient was removed from the group of patients discontinuing study due to AEs.³⁰

able representation of patien	it disposition if one study on	vonopruzun vo Eunsopruzon
Phase	Vonoprazan	Lansoprazole
Signed informed consent	n = 302	
Excluded	n = 94 (Did not meet	
	eligibility = 86, Voluntary	
	withdrawal = $6$ , Other = $2$ )	
Entered healing phase	n = 139	n = 69
Discontinued during	n = 2 (Major protocol	n = 1 (Major protocol
healing phase	deviation $=$ 1, Lost to	deviation = 1)
	follow-up = 1)	
Completed healing phase	n = 137	n = 68
Not eligible for	n = 2	n = 1
maintenance phase		
Entered 260-week	n = 135	n = 67
maintenance phase		
Discontinued during	n = 26 (Voluntary	n = 9 (Voluntary
maintenance phase	withdrawal = $13$ , Adverse	withdrawal = 6, Lost to
	event = 9, Other = $4$ )	follow-up = 1, Other = $2$ )
Received drug for >1008	n = 109	n = 58
days (included in 3-year		
interim analysis)		

### Table 2: Patient Disposition

### Table representation of patient disposition from study on Vonoprazan vs Lansoprazole:

### 2. METHODOLOGY

VISION is a 5-year, randomized, open-label, parallel-group, multicenter, phase 4 study conducted across 33 specialized medical institutions (university hospitals, general hospitals, and clinics; Additional in Japan that are experienced in conducting clinical trials in gastroesophageal reflux disease or reflux esophagitis. The study design comprises a 4 to 8-week healing phase followed by a 260-week maintenance phase [40].Patients with endoscopically confirmed erosive esophagitis (LA Classification Grades A–D) at the



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

start of treatment (week 0) were randomized in a 2:1 ratio to receive either vonoprazan 20 mg or lansoprazole 30 mg once daily for a healing phase of either 4 weeks (for patients with confirmed endoscopic healing of erosive esophagitis at week 4) or 8 weeks (for patients with no confirmed endoscopic healing of erosive esophagitis at week 4). Patients with endoscopically confirmed healed erosive esophagitis at week 4 or 8 of the healing phase then entered a 260-week maintenance phase. Healed erosive esophagitis was defined as the absence of an endoscopic mucosal break (Grade 0 according to severity classification of erosive esophagitis). During the maintenance phase, patients in the vonoprazan group were administered a starting dose of vonoprazan 10 mg once daily, and patients in the lansoprazole group were administered a starting dose of lansoprazole 15 mg once daily, for up to 260 weeks (thus a total of up to 268 weeks of treatment). Vonoprazan and lansoprazole doses were increased to 20 mg and 30 mg, respectively, if initial doses were insufficient for maintenance treatment of erosive esophagitis. Patients were randomized and allocated to treatment via a web registration system and were administered the study drugs by the principal investigator or investigator. During the healing phase, visits were planned at weeks 0 and 4, and also at week 8 for patients with no endoscopic healing of erosive esophagitis at week 4. the maintenance phase, an initial visit took place on initiation of maintenance treatment followed by visits every 12 weeks up to week 108 and visits every 24 weeks up to week 228, with a final visit at week 260.For a uniform evaluation process of endoscopic images, a standard operating procedure for the evaluation was established. A start-up meeting at each site and two seminars for all investigators were held to thoroughly inform the standard operating procedures. the delegated investigator at each study site conducted and evaluated the endoscopy. Throughout the study period, the same investigator was preferred to conduct and evaluate the endoscopy as far as possible for each patient. Is study is being and has been conducted in accordance with the Declaration of Helsinki Ethical Guidelines for Clinical Research, Clinical Trials Act (since 1 April 2018), and all applicable laws and regulations, including, without limitation, data privacy laws and conflict of interest guidelines. Before the enactment of the Clinical Trials Act, this study was conducted in accordance with the Ethical Guidelines on Biomedical Research Involving Human Subjects (the Ministry of Education, Culture, Sports, Science and Technology [MEXT] and the Minis-try of Health, Labour and Welfare [MHLW], 22 December 2014; this guideline has since been renamed the Ethical Guidelines for Life Science and Medical Research

Involving Human Subjects). Owing to the enforcement of the Clinical Trials Act in Japan on 1 April 2018, VISION was classified as a 'Specified Clinical Trial' on 21 November 2018. the transformation review was conducted at 'Certified Review Board of National Center for Global Health and Medicine' (CRB3180021) certified by MHLW, and after that the study was approved and registered under the trial ID jRCTs031180040. Prior to this classification, the study was reviewed by the Ethical Review

Boards of each study site, and informed written consent was obtained from all study participants. All authors have checked the study data and reviewed and approved the final manuscript. the study has been registered with ClinicalTrials.gov (NCT02679508, registration date 10/02/2016), JapicCTI-163153, and the Japan Registry of

Clinical Trials (jRCTs031180040)

### 2.1 Data Selection

A literature search was performed via PubMed from January 2010 to December 2022 using the search terms vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, H pylori, and gastrointestinal. All relevant English-language studies assessing the pharmacokinetics, pharmacology, efficacy, safety, or tolerability of vonoprazan were evaluated. Information was also obtained from the



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

FDA-approved package insert. References from previously published manuscripts were also examined to identify additional source Pharmacology Following food consumption, parietal cell receptors actively transport hydrogen ions across the canalicular membrane which are exchanged for luminal potassium ions. Hydrogen potassium adenosine triphosphatase (HK-ATPase) transfers equal amounts of hydrogen and potassium along with passive movement of chloride ions to promote an acidic gastric environment as well as maintain electrochemical neutrality across the membrane. The final step in gastric acid production is through the HK-ATPase, which is commonly referred to as a proton pump.5Both vonoprazan and PPIs block this final step in acid production. However, PPIs work through irreversible covalent binding to the alpha subunit of HK-ATPase whereas vonoprazan selectively and reversibly competes with luminal potassium ions required for hydrogen exchange.³¹The positively charged side chain enables strong hydrogen bonding and charge interaction with the potassium-binding site. Vonoprazan competes with potassium's binding site to prevent potassium from binding and thereby inhibiting gastric acid secretion.³²Hepatotoxicity, a problem with other P-CABs which are no longer available, is less of a concern with vonoprazan due to the absence of an imidazopyridine ring in its

chemical structure.8 Furthermore, due to the relatively high pKa value of vonoprazan (9.06), it does not require an acidic environment to bind to the enzyme and accumulates in gastric parietal cells to achieve longer-lasting gastric acid suppression. Unlike the PPIs, vonoprazan is acid stable and

does not require an acidic environment for activation nor does it require enteric coating to protect from gastric degradation.³³Pharmacokinetics Vonoprazan is rapidly absorbed with peak plasma concentration (Cmax) of 37.8 ng/mL being reached after 2 hours with a single dose and an average of 3 hours after reaching steady state with repeated dosing (tmax). The area under the curve (AUC) from administration to the end of the 12-hour dosing interval is 273 ng*hr/mL.4 Both AUC and Cmax increase dose proportionally with drug accumulation complete by the third day of treatment and little to no accumulation in plasma after repeated doses.³⁴Meals high in fat have

been shown to increase Cmax by 5%, AUC by 15%, and tmax to 5 hours; however, these differences are not considered clinically significant. Thus, vonoprazan can be administered regardless of food intake. The half-life (t1/2) is 7 to 9 hours regardless of a meal.Vonoprazan displays time-independent pharmacokinetics with steady state being reached by day 3 or 4.8 The volume of distribution (Vd) is 782.7 L with plasma protein binding of 85% to 88% and unlikely to be saturated even at drug concentrations above therapeutic range.³⁵ As previously stated, it has a relatively high pKa (9.06) resulting in near instant protonation and accumulation in gastric parietal cells within an acidic environment providing an explanation for its rapid onset, long-lasting duration of action (24 hours following a single dose and with repeated steady-state dosing), and elevated intragastric

pH following drug discontinuation (~24 to 48 hours after the last dose).³⁶ When compared to the acidreducing capabilities of a PPI, one study comparing vonoprazan to lansoprazole showed that the proportion of a 24-hour period with intragastric pH > 4 was 3-fold higher in the vonopra-

zan group after a single dose and 2-fold higher after 1 week.13Vonoprazan is metabolized via cytochrome P450 (CYP) through CYP3A4/5, CYP2B6, CYP2C19, CYP2C9, and CYP2D6 with none of its metabolites being pharmacologically active. It has also been shown to inhibit p-glycoprotein

(p-gp); however, unlikely to have any clinically significant impact on p-gp inhibition.³⁵In regards to CYP2C19 polymorphisms, there have been no confirmed differences in the pharmacokinetics of vonoprazan based on metabolizer status.³⁴Vonoprazan is predominantly excreted via the urinary tract (67%), whereas, 31% is excreted in feces. Both routes have a minimal amount of unchanged drug at



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

#### approximately 8% and 1.4%, respectively

# 2.2 PHARMACOVIGILANCE ASSESSMENT OF VONOPRAZAN THROUGH SUSPECTED ADR REPORTING AND PRESCRIPTION AUDITS

This study aims to evaluate the safety and rational use of vonoprazan, a potassium-competitive acid blocker, by analyzing data collected through suspected adverse drug reaction (ADR) reporting forms and prescription audits. The objective is to identify potential adverse effects, assess prescription trends, and promote the safe and effective use of vonoprazan in clinical practice. This pharmacovigilance approach supports early detection of drug-related problems and enhances patient safety

In support of this pharmacovigilance assessment, the Suspected Adverse Drug Reaction (ADR) Reporting Form and the Prescription Audit Template will be attached below. Additionally, relevant literature and reference documents in PDF format will be provided to ensure a comprehensive understanding of the methodology and background information related to vonoprazan safety evaluation.

	Initial C						0-3024 (1.00	AM 10 5:30	CHANG / D	CC USE ONLY	
10.1	and the second se		1 1	ollew-up	Case 🖬		Contractor International		DR ARE /	CR No. 1	
	TIENT INFOR			and the second	- Arrent and the	- State	Reg. No. /	IPD No. /	OFD No. /	CH HULL	
	illent Initials: 6		A COMPANY OF THE OWNER	a provide the second			AMC Repo	And the second se	-		
a. u.	nder: H I Fj	Diher Ci	4.Weight	(in Kg.)	62 19		Werldwid		ations with d	ates :	
1	USPECTED AD	FRISE REALT			States and	and the owner of the	13. Helevi	int meeting			
5. 1	vent / Reaction	start date (dd/r	nm/yyyy)								
6. E	vent / Reaction	stop date (dd/n	m/yyyy)								
7. 0	escribe Event/R	raction manage	ment with d	stalls , if	any						
										history (+ g	Alleroles,
							13. Releva	addiction,	hepatic, rena	dystunction et	tc.)
										ليطح	
							H			H	
							14. Cus	ness of the	reaction : N		please tick anyone
							CiDeath (de		Contraction of the	Congenital-a	nomaly
								ation-Initi	Telonged	UOther Medica	ally ortant
							15. Crem				0
							DRecovered	I DRece	overing		at Recovered
							DFatal	Diffect	overed with	requelae DUr	aknown
	USPECTED HE		and American	1	A CONTRACTOR OF THE OWNER	A DAY OF	Frequence	Thera	Dates	Indication	Causality
5.	8.	Hanufactu	1	Date	Dose	Route	Frequency	Date	Dates Date	Indication	Causality
	B. Name (Brand/	Hanufactu	Lot	Date	Dose	Route	Frequency	Date Started	Date Stopped		
5.	8. Name	Hanufactu	1	(if known)	Dose f.c.roy	Route	Frequency	Date Started	Date		
5. Na. I	8. Name (Brand/ Generic)	Hanufactu rer (If known)	Lot Ne.	(if known)	-		Frequency	Date Started	Date Stopped		
5. No. I II	8. Hame (Brand/ Generic) Voniona	Hanufactu rer (If known)	Lot Ne.	(if known)	-		Frequency	Date Started 4-12-24	Date Stopped	pun	Assessment
5. No. 1 11 111	8. Name (Brand/ Generic) Noniong (Johophata	Manufactu rer (if known)	/ Lot No. AAFAYday	(if known)	-		Frequency	Date Started 4-12-74	Date Stopped 10-12-24	ກມກ red after reintro	Assessment
5. No. 1 11 111	8. Name (Brand/ Generic) Voniona (vono prosta	Hanufactu rer (if known) 45	Lot No. AAFAwday o Uck)	Date (if known) /-7-20	iany	Qro!		Date Started 4-12-74 10. Reac	Date Stopped 10-12-24	ກມກ ved after reintro	Assessment oduction of (A) Dose
5. No. I II III 9. / 5.	8. Name (Brand/ Generic) VOD/ong Uphophola Uphophola Con taken after Drug	Manufactu rer (if known)	/ Lot No. AAFAYday	(if known)	ra my	QTO/	Frequency	Date Started 4-12-74	Date Stopped 10-12-24	ກມກ ved after reintro	Assessment
5. Na. 1 11 11 11 9. 5. No.	8. Name (Brand/ Generic) Voniona (vono prosta	Hanufactu rer (if known) (if known) (if known) (if known) (if known) (if known)	Lot No. AAFAxcey e UCA) Dose	Date (if known) / 7-20	ra my	QTO/		Date Started 4-12-74 10. Reac	Date Stopped 10-12-24	PUD red after reintro	Assessment aduction of b Dose
5. No. 1 11 11 11 9. No.	8. Name (Brand/ Generic) VOD/ong Uphophola Uphophola Con taken after Drug	Hanufactu rer (if known) (if known) (if known) (if known) (if known) (if known)	Lot No. AAFAxcey e UCA) Dose	Date (if known) / 7-20	ra my	QTO/		Date Started 4-12-74 10. Reac	Date Stopped 10-12-24	PUD red after reintro	Assessment
5. Na. I II III 9. S. No. er C	8. Name (Brand/ Generic) VOD/ong Uphophola Uphophola Con taken after Drug	Hanufactu rer (if known) (if known) (if known) (if known) (if known) (if known)	Lot No. AAFAxcey e UCA) Dose	Date (if known) / 7-20	ra my	QTO/		Date Started 4-12-74 10. Reac	Date Stopped 10-12-24	PUD red after reintro	Assessment
S. No. 1 1 1 1 1 1 1 1 1 1 1 1 1	8. Name (Brand/ Generic) VOD/ong Uphophola Uphophola Con taken after Drug	Hanufactu rer (if known) (if known) (if known) (if known) (if known) (if known)	Lot No. AAFAxcey e UCA) Dose	Date (if known) / 7-20	ra my	QTO/		Date Started 4-12-74 10. Reac	Date Stopped 10-12-24	PUD red after reintro	Assessment
S. No. 1 11 111 9, 7 No. 11 11 11 11 11 11 11	8. Name (Brend) Generic) Noniong Loncondra Uniong Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncondra Loncon	Hanufactier (If known) ant reaction (pleased incressed	Adraway e Uck) Dose reduced	Dete (if known) /-7-20 Dose n change	ot phi	Oro/	Unknown	Dete Started 4-12-24 10. Reac Susp Yes	Date Stopped 10-12-24	PUD red after reintre atton (please Min Effect unknow	Assessment oduction of (a) Dose (if re- introduced)
S. No. 1 11 111 9, 7 No. 11 11 11 11 11 11 11	8. Name (Brend) Generic) Noniong Loncondensity clion taken after Drug withdrawn	Hansfelt (If known) reaction (pleas Incressed	Adraway e Uck) Dose reduced	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/	Unknown	Date Started 4-12-24 10. Reac susp Yes	Date Stopped 10-12-24	PUD red after reintre atton (please Min Effect unknow	Assessment oduction of (if re- (introduced)
S. No. 1 11 11 9. 5. No. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornobia cuon taken after Drug withdrawn Concomilant me feme	Hansfelt (If known) reaction (pleas Incressed	Alt Arces	Dete known) /·7=2C Dose n change	ot phi	Oro/	Unknown with therapy d	Date Started 4-12-24 10. Reac susp Yes	Date Stopped 10-12-2-9 Uon reapped ected medic No	PUD ved after reintro atton (presse Mice Effect unknow	Assessment oduction of (if re- (introduced)
S. No. 1 11 11 11 11 9. 7 5. 8 8 8 7 1 11 11 11 11 12 5. No. 8 8 8 8 8 8 8 1 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornobia cuon taken after Drug withdrawn Concomilant me feme	Hansfelt (If known) reaction (pleas Incressed	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/	Unknown With therapy d Therapy	Date Started d - 12-24 10. Reac susp Yes ates (Exclust Dates	Date Stopped 10-12-2-9 Uon reapped ected medic No	PUD ved after reintro atton (presse Mice Effect unknow	Assessment oduction of (if re- (introduced)
S. No. 1 11 11 11 9. 7 S. 8 S. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornobia cuon taken after Drug withdrawn Concomilant me feme	Hansfelt (If known) reaction (pleas Incressed	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/	Unknown With therapy d Therapy	Date Started d - 12-24 10. Reac susp Yes ates (Exclust Dates	Date Stopped 10-12-2-9 Uon reapped ected medic No	PUD ved after reintro atton (presse Mice Effect unknow	Assessment oduction of (if re- (introduced)
S. Na. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/	Unknown with therapy d Therapy Started	Date Started d -12-24 10. Reac susp Yes Yes Dates (Exclude Dates Date Stop	Date Stopped 10-12-2-9 Uon reapped ected medic No	PUD ved after reintro atton (presse Mice Effect unknow	Assessment oduction of (if re- (introduced)
S. Na. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornobia cuon taken after Drug withdrawn Concomilant me feme	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ cable medles Date	Unknown with therapy d Therapy Started	Date Started d -12-24 10. Reac surp Yes Ves Ates (Eacture Dates Date Stop	Date Stopped 10-12-24 tion reappea ected medic No de those use	PUD ved after reintre after (crease Ho Effect unknow d to treat reacti Endici	Assessment oduction of (i) Dose (if re- (if re- introduced) ion) atten
S. Na. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ et cable Date	Unknown with therapy d Therapy Started	Date Started d-12-24 10. Reac xusp Yes Ates (Exclus Dates Dates Date Step	bate Stopped 10-12-24 tion reappea ected medic No de those use sped	PUD red after reintro atton (please Mic Effect unknow d to treat reaction Endicion	Assessment oduction of (i) Dose (if re- introduced) ion) ation
S. Na. 1 11 11 11 11 11 11 11 11 11 11 11 11	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ ot cable Date	Unknown with therapy d Therapy d Started POBTER DIT ame & Address	Date Started d -12-24 10. Reac sup Yes Yes Atts (Exclude Dates (Exclude Date Stop	bate Stopped 10-12-24 tion reapped ected medic: No de those use oped - Hard	PUD red after reintro ation (press the Effect unknow d to treat reaction Endicion Scot Pont	Assessment oduction of (i) Dose (if re- introduced) ion) atten
S. No. 1 1 1 1 1 1 1 1 1 1 1 1 1	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ ot cable Date	Unknown with therapy d Therapy Started PORTLA DIA ame & Address PAN924716 Em	Date Started d -12-24 10. Reac sup Yes Yes Atts (Exclude Dates (Exclude Date Stop	bate Stopped 10-12-24 tion reapped ected medic: No de those use oped - Hard	PUD red after reintro ation (press the Effect unknow d to treat reaction Endicion Scot Pont	Assessment oduction of (i) Dose (if re- introduced) ion) ation
S. No. 1 1 1 1 1 1 1 1 1 1 1 1 1	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ cable Date 0. Rf 15. N Date 26. N Date	Unknown with therapy d Therapy Started PORTLA DIA ame & Address PAN924716 Em	Date Started d-12-24 10. Reac sup Yes Yes Alts (Eactur Dates (Eactur Dates top Date Stop	bate Stopped 10-12-24 Iton reappea ected medic No de those use sped k Yaxi - May 20	PUD red after reintre ation (ofease Mic Biffect unknow d to treat reaction to treat reaction to treat reaction SCDL Par SCDL Par SCDL Par SCDL Score Score	Assessment oduction of (i) Dose (if re- introduced) ion) atten
S. No. 1 1 1 1 1 1 1 1 1 1 1 1 1	8. Name (Brend) Generic) Vohiong Uphornoba cuon taken after Drug withdrawn Concomilant me (Brand / Gen	Hanufactier (If known) reaction (plean Dose Increased bical product inc eric)	Alt Arces	Dete known) /·7=2C Dose n change	ot Price Pri	Oro/ ot cable Date	Unknown with therapy d Therapy d Started POBTER DIT ame & Address	Date Started d -12-24 10. Reac sup Yes Yes Atts (Exclude Dates (Exclude Date Stop	bate Stopped 10-12-24 tion reapped ected medic: No de those use oped - Hard	PUD red after reintro ation (press the Effect unknow d to treat reaction Endicion Scot Pont	Assessmen oduction of (h) Dose (if re- introduce introduce

1



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

# Prescription Audit for Vonoprazan

### 1. Prescription Detail

Чų

- > 2
- Prescriber Name. V. Dr. Pan Kai welling > Date of Prescription...4-12-24
- 4 Diagnosis/Indication D Yes D No
- 2. Drug & Dosage Appropriateness
  - 2
    - Indication Appropriate (GERD,PUD, H.pylori,etc): -Yes D No A
    - Dose & Strength (10 mg / 20 mg) Appropriate: -Yes No Þ
  - Duration Specified & Appropriate: Yes No
- H. pylori Eradication Regimen (if applicable): 2.1. >
  - Vonoprazan + Amoxicillin + Clarithromycin/Metronidazole Correctly Prescribed: 
    Yes 
    No
  - Duration of 7-14 Days Mentioned: 🗗 Yes 🗆 No >
- 3. Safety & Drug Interactions
  - Any Contraindications Checked (e.g., Liver Disease, Þ Pregnancy)? I Yes I No
  - 4 Drug Interactions Considered (e.g., CYP3A4 Drugs, Anticoagulants)? - Yes - No
  - Renal/Liver Function Checked (if necessary)? -Yes No 8
  - Risk of Long-term Use (Osteoporosis, Hypomagnesemia) N Considered? Ves D No
- 4. Patient Instructions & Adherence
  - Clear Instructions on Timing with Meals: -Yes D No >
  - Patient Advised on Possible Side Effects: D Yes D No 2
  - 8 Advised to Complete Full Course (If for H. pylori)? - Yes No
- 5. Cost & Accessibility Considerations:
  - Generic or Cost-effective Brand Considered: Ves D No >
  - > Availability Confirmed: D Yes D No

Total "Yes" Responses: .!.4./15

Auditor Name & Date: Aipar 1998 2000 pawar (11-3-25)



E-ISSN: 2582-2160 • Website: www.ijfmr.com

• Email: editor@ijfmr.com

1 4		maran	HARMACOP	OEIA CO	MMISSION		ADAs by Heal	lincare Prof	essionals mecodo fai	nie Press	mme of In	
-			marit ni ufa	Ith & Pam	ly Welfare, Gi	overnmen	nt of India, Se	ctor-23, Ra;	Nagar, Cl	-bedeiser	201002	ora)
	Initial C					00-180	3024 (5:00 /	COLUMN TWO IS NOT	COLUMN TWO IS NOT	The owner where	State of the local division of the local div	
A. PA	TIENT INFORM	ATION	and in case of the local division of the loc	Hew up (	Me 🗆	The state of the			R AMC / I			
1. Pat	tient Indials	COMA PORTA	2. Apr ar	date of ti	m 60	2 2 10	Reg. No. /	the real Party is not the owned	OPD No.	CR No.	1	
3. Get	nder: H 2 FC	Other G	4.Weight		60		Worldwide		-			
. 50	SPECTED NOV			089785	0.0	-	12. Releva	THE OWNER WHEN THE OWNER		dates		
5. Ev	ent / Reaction s	AND date (dd)	10N -		1-1-11			155				
0. LV	ent / Reaction s	top date idd/	the second second									
7. De	scribe Event/Re	action manage	ement with de	tells , if a	ný							
							13. Releval pregnancy,					gies,
							P			1	Ľ'	
							UDeath (de	(mm/yyyy)	eaction :	UCong	ental-anor	se lick anyone) Navy
							Cui rea		Toknow	DDisa	Medically	Instant
							15. Cen	10 1 C 10	]	- arcrise	Turner	
							ORecovered	d DReco	veving		UNot R	ecovered
C. S.	SPI CTED HE	TEATLONG ST		_	-		DFatal	DReco	overed with	sequela	e Dülakna	we.
5.	8.		u Batch No.	Expiry	Dose	Route	Frequency	Theres	y Dates	Indi	cation	Causality
Nc.	Name (Brand/ Generic)	(if known	No.	Date (If known)				Date Started	Date			Assessment
1	VOROPEALO		MAKA X003	C1/07/21	long c	1p30		22/11/24	29/11/2	4 P	UD	
10	Vohalon	1	-		0			-		-		
le"		_								-		
9. A	tion taken after	reaction (play	an ack)		*			10. Read	tion reapp	eared aft	er reintrodu	etion of
5.	Drug	Dose	Dose	Dose n	ot N	ot	Unknown		ected med	lication ()	Effect	12230
No.	withdrawa	Increased	reduced	change						10	unknown	Dose (If re- Introduced)
er c			-		-	_		-	-			
ier C						-	-	-	-	-	-	
er C									-	-		
I II		dical product is		medication	and herbal n	emedies	with therapy o	dates (Exclu	de thase u	sed to ti	eat reaction	1
IIIIIII	Concomitant me	eric) Dos	e Ros	ate Fre	BD, etc.)		Therapy Started	Dates Date Sto	pped		Indicati	lon
II II III IV 11. (	Concomitant me Name (Brand / Gen			-								
II II III IV 11. (	Name											
er C 1 11 111 111 12. ( 5. Mo. 1 1	Name					-				_		
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	(Brand / Gen					-						
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	Name	tion :				_	PORTER DET	a second s	60 D			and the second
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	(Brand / Gen	tion :				16. 8	ame & Addres	a: Tei	as P	nda	2	
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	(Brand / Gen	tion :				16, 8	ame & Addres	H: Teji	howk	)	N	1.(07
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	(Brand / Gen	lion :				16, 8	ame & Addres	H: Teji	howk	)	N	l-com
er C 1 11 111 111 112 13. ( 1 1. ( 1 11 11) 111 111	(Brand / Gen	lian :				16, 8	ame & Addres	H: Teji	howk	)	N	l:com



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

### Prescription Audit for Vonoprazan

### 1. Prescription Detail

- Patient Name . Rozzeka ... P.M.V.Can >
- Prescriber Name. Rt. Byed Azbur. Abernad >
- Date of Prescription .. 2.7- 91-2.4..... 2
- Diagnosis/Indication D Yes D No >
- 2. Drug & Dosage Appropriateness
  - Indication Appropriate (GERD, PUD, H.pylori, etc): 2 Yes 2 No >
  - Dose & Strength (10 mg / 20 mg) Appropriate: 🖬 Yes 🗆 No 7
  - Duration Specified & Appropriate: 🖾 Yes 🗆 No 4
- H. pylori Eradication Regimen (if applicable): 2.1.
  - Vonoprazan + Amoxicillin + Clarithromycin/Metronidazole > Correctly Prescribed: 
    Yes 
    No
  - Duration of 7-14 Days Mentioned: 
    Yes 
    No >
- 3. Safety & Drug Interactions
  - Any Contraindications Checked (e.g., Liver Disease, > Pregnancy)? Ves 🗆 No
  - Drug Interactions Considered (e.g., CYP3A4 Drugs, * Anticoagulants)? TYes D No
  - Renal/Liver Function Checked (if necessary)? 🖾 Yes 🗆 No >
  - Risk of Long-term Use (Osteoporosis, Hypomagnesemia) 2 Considered? 2 Yes D No
- 4. Patient Instructions & Adherence
  - Clear Instructions on Timing with Meals: 2 Yes D No >
  - Patient Advised on Possible Side Effects: 2 Yes D No >
  - Advised to Complete Full Course (If for H. pylori)? 
    Yes > No
- 5. Cost & Accessibility Considerations:
  - Generic or Cost-effective Brand Considered: 2 Yes D No >
  - Availability Confirmed: Yes I No >

Total "Yes" Responses: 12 ... /15

Auditor Name & Date: .. Tojas ... V. fendor [28-02-2025



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

Sust Sust Sust Sust Sust Sust Sust Sust	PECTED MEE 8. Name (Brand/ Grand/ Grand/ Ono Procer mox/ Official	ATTON -	PePI H F 2. Age or 4. Weight mm/yyyy) ment with do Batch No.	Expin Date (if Ke)	Y Dose	DN (m re. Gay ) : 1800	enner	ADRs by Heal     Coordination (     nt of India, Se     -3024 (9:00 /     Reg. No. /     AMC Report     Worldwide     12. Releval     13. Releval     12. Releval     14. Cluss     Obeath (of     Obeath     O	Centre-Phar ctor-23, Ray AM 10 5:30 1 FO JPD No. / t No. Unique No nt investiga nt medical / addiction, h ness of the Umm/yyyy) tening ation-Initi ne: 5 Reco Direct	macovigilan Nagar, Gh. 'H, Honday AMC / M OPD No. / 2 . : ions with d medication epatic, renu reaction : N	Aniabad-2010 - Friday) (C USE offi CR No. 1 (ates 1 - history (e.g. M dysfunction 	Aller etc.) I (plea di-anon dically Dinat Ro	rgies, Se Nck anyone) haiy ortant iecovered
SUS SUS SUS SUS Sus Sus Sus Sus Sus Sus Sus Sus Sus Su	PECTED HEE B: Constant B: Con	ATTON -	PePI H F -2. Age or 4. Weight m/Yyyy) m/Yyyy) ment willb do Batch No. / Lot No.	Expin date of (m Kg ) etails , if	(Toll Free Case ] Dirth: G GO fany	2 2 R	oute		AM to 5:30 1 JPD No. / IPD No. / t No. Unique No. Unique No. Unique No. Int medical / addiction, h ness of the (Imm/yyyy) tening addiction, h ness of the Imm/yyyy) tening addiction, h ness of the Imm/yyyy) tening Date Date	Nagar, Gh. PH, Honday AMC / N OPD No. / 1 b.: ions with d medication epatic, renu reaction : N colonged vering vered with Date	Aniabad-2010 - Friday) (C USE offi CR No. 1 (ates 1 - history (e.g. M dysfunction 	Aller etc.) I (plea di-anon dically Dinat Ro	rgies, se Nck anyona) haiy ortant ecovered own Causality
SUST SUST SUST SUST SUST SUST SUST SUST	PECTED HEE B: Constant B: Con	ATTOK 2 ATTOK 2 Context of the second seco	F. 4.Weight ( che- m/yyyy) ment with do Batch No. / Lot No.	Expin Date (if Expin	y Dose	2 R	oute	Reg. No. /     Reg. No. /     AMC Report     Worldwide     12. Releval     I3. Releval     I3. Releval     I4	AM 10 5:30 1  IPD No. /  IPD No. /  IPD No. /  IPD No. /  Ini ness of the  Imm/yyyy)  tening  Addiction, h  ness of the  Imm/yyyy)  tening  Character  Date  Therag  Date	PH, Honday AMC / N OPD No. / 1 . : . : . : . : . : . : . : . :	A history (e.g. history (e.g. dysfunction io if i Congenta Dosability Other Med sequelae	aller etc.) i (plea il-anon sically Dink R DUnkno	se Ack anyone) haly detant ecovered over
SUST SUST SUST SUST SUST SUST Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust Sust	PECTED HEE B: Constant B: Con	Cither Cites	Batch No.	Expin Date (If Kg )	y Dose	2	oute	Arcg. No. / AMC Report Worldwide 12. Releval 13. Releval pregnancy, 14. dus Obeath (66 Olian rea OHd all 15. dus OFatal	IPD No. / IPD No. / It No. Unique No. Unique No. IUnique No. In investigation Int investigation Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Interview Intervie	RAMC/N OPD No. / 1 .: iions with d medication epatic, renu reaction : N relonged vering vering vering vering vering bate	A history (e. g. history (e. g. history (e. g. dysfunction Congenia Disability Dother Mec sequelae	aller etc.) I (plea II-anom dically Unkot R DUnkno	se Ack anyone) haly detant ecovered over
SUSP SUSP Event Event Event Descri U S S S S S S S S S S S S S	PECTED HER Berley Holder I / Reaction s I / Reactio	Cither Cites	4. Weight c). ( im/yyyy) im/yyyy) ment with do Batch No. / Lot No.	Expin Date (if known	CD (any ) Dose	R		AMC Report Worldwide 12. Releval 13. Releval pregnancy. 14. ous Obeath (66 Oligonal Obeath (66 Oligonal Chick Construction Of and OF and	IPD No. / it No. Unique No. Unique No. Unique No. Unique No. Addiction, h ness of the Umm/yyyy) dening abion-Init[ abion-Init] abion-Init[ Date Date	OPD No. / i .: medication epatic, renu reaction : N polonged vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering ve	CR No. 1	aller etc.) I (plea II-anom dically Unkot R DUnkno	se Ack anyone) haly detant ecovered over
SUSS Event S. Event J. Descri J. Descri S. No. II Uo III CO III CO III CO III CO III CO III CO III III	PECTED MEE 8. Name (Brand/ Grand/ Grand/ Ono Procer mox/ Official	DICATION(S) Manufactu Manufactu (If known)	4. Weight c). ( im/yyyy) im/yyyy) ment with do Batch No. / Lot No.	Expin Date (if known	CD (any ) Dose	R		AMC Report Worldwide 12. Releval 13. Releval pregnancy. 14. ous Obeath (66 Oligonal Obeath (66 Oligonal Chick Construction Of and OF and	nt medical / addiction, h ness of the //mm/yyyy) sening abion-Init abion-Init Date Date Date	: medication medication epallic, renu reaction : N rolonged vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering vering veri	Indication	l (plea I (plea I anon dically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
SUSS Event S. Event J. Descri J. Descri S. No. II Uo III CO III CO III CO III CO III CO III CO III III	PECTED MEE 8. Name (Brand/ Grand/ Grand/ Ono Procer mox/ Official	DICATION(S) Manufactu Manufactu (If known)	4. Weight c). ( im/yyyy) im/yyyy) ment with do Batch No. / Lot No.	Expin Date (if known	CD (any ) Dose	R		Worldwide 12. Releval 13. Releval 14. cus Obeath (ed Oblatin (ed O	Unique No ni investiga ni investiga ni medical / addiction, h ness of the (/mm/yyy) adion-fait adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yyy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) adion-fait (/mm/yy) (/mm/yy) adion-fait (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy) (/mm/yy)	medication epatic, rena reaction : N polonged vering vering vering vering vering vering vering vering vering vering	history (e. g. digsfunction loo if Ocongenta Dosability Other Med sequelae	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
S. Event S. Event P. Descri S. Vo. I U.c II U.c II V.c II V.c II V.c II II II	Periodicians I / Reaction s I / Reaction s I / Reaction s I / Reaction s I / Reaction s Reme (Brand/ Generic) Constancy mox/ chini	DICATION(S) Manufactu (If known)	Batch No.	Expin Date (if	y Dose			12. Releval 13. Releval 14. cus 14. cus CDEBTR (ce CDEB	nt investiga nt medical / addiction, h ness of the l/mm/yyyy) adion-Init[ adion-Init] adion-Init[ di Data Data	medication epatic, rena reaction : N polonged vering vering vering vering vering vering vering vering vering vering	history (e. g. digsfunction loo if Ocongenta Dosability Other Med sequelae	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
S. Event S. Event P. Descri S. Vo. I U.c II U.c II V.c II V.c II V.c II II II	Periodicians I / Reaction s I / Reaction s I / Reaction s I / Reaction s I / Reaction s Reme (Brand/ Generic) Constancy mox/ chini	DICATION(S) Manufactu (If known)	Batch No.	Expin Date (if	y Dose			13. Relevan pregnancy, 14. dus Obeath (66 Olio rea OHd allz 15. door ORecovered OFatal	nt medical / addiction, h ness of the (/mm/yyyy) ation-Init ation-Init ation-Init ation-Init ation-Init ation-Init Bate Date	medication epails, renu reaction : N rolonged vering vering vering vering vering vering	history (e. g. digsfunction loo if Ocongenta Dosability Other Med sequelae	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
S. SUSP S. Vo. III U.c. III O.C. III A. WI S. Action S. Action III III	Pentonia Name (Brand) Constant Mame (Brand) Constant Mame (Brand)	DICATION(S) Action manage DICATION(S) Manufactu rec (iff known)	Batch No.	Expin Date (if	y Dose			14. cus Death (cd Dhata 15. con DRecovered DFatal	Addiction, h ness of the (/mm/yyyy) tening ation-Initi me: 5 DReco Date Date	reaction : N reaction : N olonged vering vered with y Dates Date	io if Disability Disability Dother Med	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
S. 51153 S. Ve. II U.e II O.e II A.s V ² 9. Action S. Wi s s c I II	PECTED MET 8. Name (Brand/ Grandiany mov. chini	DICATION(S) Manufacture (If known)	Batch No. / Lot No.	Expin Date (if	y Dose			14. cus Death (cd Dhata 15. con DRecovered DFatal	Addiction, h ness of the (/mm/yyyy) tening ation-Initi me: 5 DReco Date Date	reaction : N reaction : N olonged vering vered with y Dates Date	io if Disability Disability Dother Med	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
S. 5USS S. No. II U.e II 0.0 II A.s V ² 9. Action S. wi s s c I II II	BERTEO MET 8. Name (Brand/ Genetic) onotrolony mox/dim	DICATION(S) Hanufactu ret (if known)	Batch No. / Lot No.	Expin Date (if	y Dose			14. cus Death (cd Dhata 15. con DRecovered DFatal	Addiction, h ness of the (/mm/yyyy) tening ation-Initi me: 5 DReco Date Date	reaction : N reaction : N olonged vering vered with y Dates Date	io if Disability Disability Dother Med	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				14. cus Death (cd Dhata 15. con DRecovered DFatal	Addiction, h ness of the (/mm/yyyy) tening ation-Initi me: 5 DReco Date Date	reaction : N reaction : N olonged vering vered with y Dates Date	io if Disability Disability Dother Med	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				14. cus Death (cd Dhata 15. con DRecovered DFatal	Addiction, h ness of the (/mm/yyyy) tening ation-Initi me: 5 DReco Date Date	reaction : N reaction : N olonged vering vered with y Dates Date	io if Disability Disability Dother Med	l (plea I (plea I anon Sically Dinat R Dunkna	se Ack anyone) haly detant ecovered over
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				Death (dd DLimreal DHcmaliz 15. Con DRecovered OFatal	Umm/yyyy) tening ation-Initi ne: DReco DReco Therap Date	vering vering vered with y Dates Date	Congenia Disability Dother Med sequelae	l·anon dically DNot R DUnikno	ertant ecovered own
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				Death (dd DLimreal DHcmaliz 15. Con DRecovered OFatal	Umm/yyyy) tening ation-Initi ne: DReco DReco Therap Date	vering vering vered with y Dates Date	Congenia Disability Dother Med sequelae	l·anon dically DNot R DUnikno	ertant ecovered own
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				Death (dd DLimreal DHcmaliz 15. Con DRecovered OFatal	Umm/yyyy) tening ation-Initi ne: DReco DReco Therap Date	vering vering vered with y Dates Date	Congenia Disability Dother Med sequelae	l·anon dically DNot R DUnikno	ertant ecovered own
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				Death (dd DLimreal DHcmaliz 15. Con DRecovered OFatal	Umm/yyyy) tening ation-Initi ne: DReco DReco Therap Date	vering vering vered with y Dates Date	Congenia Disability Dother Med sequelae	l·anon dically DNot R DUnikno	ertant ecovered own
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				DLI rea DHd_aliz 15. Con DRecovered DFatal	tening ation-Initiane: a OReco OReco Therap Date	vering vered with y Dates Date	Disability Dother Med sequelae	Sically Disct R JUnikno	ecovered own
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				15. Con ORecovered OFatal	ne: DReco DReco Therap Date	vering vered with y Dates Date	sequelae D Indication	JNat R JUnkna	ecovered two Causality
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				GRecovered OFatal	DReco DReco Therap Date	y Dates Date	Indication	Unikna	Causality
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				OFatal	Therap Date	y Dates Date	Indication	Unikna	Causality
5. 1 Up 1 Up 1 Up 1 Up 9. Action 9. Action 9. Action 1 1	8. Name (Brand/ Generic) prophotor providing mox/dim	Manufactu rer (if known)	Batch No.	Date (If				Frequency	Therap	y Dates Date	Indication		Causality
I Uo II Oo III A 1 V ² 9. Action S. wi II II II	Name (Brand) Generic) enceptozer omolany moxidiji	ni (if known)	Lot No.	Date (If				Frequency	Date	Date			
II Co III A - V 9. Action 5. Wi 5. No. Wi 5. I 1 II	onoprozor oriulany moxidili			1+07-1	20 arong	H OTO	Lu Co						
II A	moxidiin	ň			- 0"				18-12-24		A AND AND A		
9. Action S. Wi I I II		ň –				1	1	-	10-112-25	21-12-24	H-PAID	5	
9. Action S. wi No. wi er C I	1000		-									-	
S. No. wi er C I II		1								C			
No. wi er C I II	on taken after	reaction (pleas	se lick)						10. Reac	tion reappe	ared after rel	ntrodu	ction of
er C I II	Drug withdrawn	Dose Increased	Dose	Dose chan		Net		Unknown	Yes	ected media No		ect	Dose
11						216					unio	town	(if re- introduced)
							-	-	1			-	
10										-		_	
the second second												-	
IV Con				1									
		fical product in Dose	ciuding self-	medicati	ion and her	bai ren	nedles	with therapy d	ates (Exclu	de those us			
. No. (8	Brand / Gen	eric)			BD, etc	500,	Bat	Therapy			In	dicatio	on
1		_			_	-	Dece	e Started	Date Stop	ped			
				-		-							
				-	_				_	-		_	
	nal Informat	tion :					D. 88	PORTER DET	TAILS *	S PARTY NO	Contraction of the	-	A DECEMBER OF
022012						1	16. N	ame & Addres	a: Tejo	selini f	Jondo	617	mpode
							01-1	Sodgaan	Ty. Dore	the Bis	- Youaln	na t	and the same first test
							Pin 1	445202 H	mail : Lopa	winigh	erpor dela	agar	nail com
							Contai	ct No-: 709	751241	2		1	
							Occup	ation : Phore	nesis//si	untimit si	gnature :	-the	1.42
				-			17. 0	tate of this r	top) twee	mm/yyyy)	1	-	and the second sec
Signatur	ire and Nam	e of Receivin	g Personne	1.	bilet month		-						

Mandatory Fields for suspected ADR Reporting Form

E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

### Prescription Audit for Vonoprazan

### 1. Prescription Detail

- Patient Name Simo 9 asdare >
- 4 Prescriber Name. Sunit Mondon
- > Date of Prescription.......
- 4 Diagnosis/Indication D Yes D No
- 2. Drug & Dosage Appropriateness
  - Indication Appropriate (GERD, PUD, H.pylori, etc): Yes I No >
  - Dose & Strength (10 mg / 20 mg) Appropriates. I Yes I No >
  - Duration Specified & Appropriate: 2 Yes 2 No
  - > H. pylori Eradication Regimen (if applicable):

#### Vonoprazan + Amoxicillin + Clarithromycin/Metronidazole 2.1. >

- Correctly Prescribed: Ves I No
- Duration of 7-14 Days Mentioned: 1 Yes I No 3
- 3. Safety & Drug Interactions
  - Any Contraindications Checked (e.g., Liver Disease, 8
    - Pregnancy)? 🖾 Yes 🗆 No
    - Drug Interactions Considered (e.g., CYP3A4 Drugs, > Anticoagulants)? 🖾 Yes 🗆 No
    - Renal/Liver Function Checked (if necessary)? □ Yes □ No
    - Risk of Long-term Use (Osteoporosis, Hypomagnesemia) > 8
    - Considered? Yes I No

### 4. Patient Instructions & Adherence

- Clear Instructions on Timing with Meals: 2 Yes D No >
  - Patient Advised on Possible Side Effects: Tyes D No >
  - Advised to Complete Full Course (If for H. pylori)? D Yes D >
- No 5. Cost & Accessibility Considerations:
  - Generic or Cost-effective Brand Considered: ☐ Yes □ No
    - Availability Confirmed: 🖾 Yes 🗆 No >

Total "Yes" Responses: 15./15

Auditor Name & Date: Tejaswini M. Gnorpode [ 13 11/26]



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

100		Ļ	went Ph	ARMACOP	OEIA CO	MMISSION		ADRs by Heal	thcare Prof	essionals	1992 (S. 1997) 1992 (S. 1997)		4143
T.d	· · · · ·	_				the second second		nt of India, Sec -3024 (9.00 A	(Int. 31 Pa.	Manage Cha	and the set of the	01002	ara)
No.	Initial CL				New-up (				the second second second	R AMC / N	and the second se		
	TIENT INFORM			and some of	Electron and	No. of Lot of Lo	100	Reg. No. /	IPD No. /	OPD No. /	CR No. 1	NLY	
	Hent Initials: H-			2. Age ar	the second s	irth: 21		AMC Repor		1			
A. UC	nder: M 🖬 F 🔉	Othe		4.Weight (	in Kg )	31 19		Worldwide	Unique N	a. :			
16.51	ISPECTED ADV	FRSE	EAGTER	DN *		and the Real Property lies	Start.	12. Relevar	nt investiga	cions with d	lates :		
S. Ev	ent / Reaction s	tart da	le (dd/m	m/yyyy)									
7. De	ent / Reaction s scribe Event/Re	top dat	e (dd/m	(ייייליד	and a								
	are any fig	11100	managen	nent with de	stations , of a	mγ							
								13. Relevar pregnancy, i	addiction, h	epatic, ren	el dysfunct	tion etc.)	
				it.				14. cusr Death (dd DH real Hd alsz 15. corr DRecovered DFatal	//mm/yyyy) tening ation-Initi ne: 1 DReco	-	DConge Dbrabil D0ther	ntal-anon lity Medicaty	ecovered
C S	USPECTED ME					and the second	-	MAX TO A ST	1.	Sec. 1	We see	1.000	
S. 1		100	rer	Batch No.	Expiry Date	Dose	Route	Frequency	Theray		Tadiat	tion	
S. Ne,	Name (Brand/ Generic)	(H	known)	Lot	(If				Date Started	Date	Indica		Causality Assessment
No.	Name (Brand/ Generic) Vonolong		known)	Lot No. A4ka-log	(If known)		oyal		Date Started	Date Stopped			
Ne. 1	Name (Brand/ Generic) Venelang Venelang	ant	known)	No.	(If known)		Caral I		Date Started	Date			
Ne. 1 11	Name (Brand/ Generic) Vonolong	ant	known)	No.	(If known)		Gya!		Date Started	Date Stopped			
Ne. 1 11 111	Name (Brand/ Generic) Van of cong Van of cong Anno a sicilii	an)+ in		No. A4ta Xog	(If known)		Graf		Date Started S-12-14	Date Stopped 12-12-9	E H P.J	llari reintrodu	Assessment
Ne. 1 11 11 11 11 9. A 5. No.	Name (Brand/ Generic) Venelang Venelang	an)+ m reaction		No. A4ta Xog	(If known)	10 PDg	Gyral I fot licable	Unknown	Date Started S-12-14	Date Stopped	t H P-y	llari reintrodu	Assessment uction of Dose (if re-
No. 1 1 1 1 1 1 1 1 1 1 1 1 1	Name (Brand/ Generic) Nonopican Anna xio/11/ ction taken after Drug	an)+ m reaction	an (pleas	No. A4tA deg e lick) Dose	(If known) I-J-2:	10 PDg	iot	Unknown	Date Started S-12-24 10. Read Susp	Date Stopped 12-12-9/ ction reappoint	t H P-y	Idri reintrodu oase lick)	Assessment uction of Dose
Ne. 1 11 111 117 9. A 5. No. as	Name (Brand/ Generic) Nonopican Anna xio/11/ ction taken after Drug	an)+ m reaction	an (pleas	No. A4tA deg e lick) Dose	(If known) I-J-2:	10 PDg	iot	Unknown	Date Started S-12-24 10. Read Susp	Date Stopped 12-12-9/ ction reappoint	t H P-y	Idri reintrodu oase lick)	Assessment uction of Dose (if re-
No. I II IV 9. A No. 85 er C I III III	Name (Brand/ Generic) Nonopican Anna xio/11/ ction taken after Drug	an)+ m reaction	an (pleas	No. A4tA deg e lick) Dose	(If known) I-J-2:	10 PDg	iot	Unknown	Date Started S-12-24 10. Read Susp	Date Stopped 12-12-9/ ction reappoint	t H P-y	Idri reintrodu oase lick)	Assessment uction of Dose (if re-
Ne, 1 1 1 1 1 9, A 5, No, as er C 1 11 11 11 11 11 11 11 11 11	Name (Brand/ Generic) Von olong Von oppose Chon sie / // Ction taken after Drug withdrawn	නවා න reaction incr	an (pleas ose eased	No. <u>AdkAde</u> e lick) Dose reduced	(If known) I-J-20 Dose t chang	not spi	iot liceble		Date Started S-12-20 10. Read susp Yes	Data Stopped 12-12-74 clion reappy acted medi	Eared after cated after u	Idri reintrodu ase rick) Effect nknown	Assessment uction of Oose (if re- introduced)
No. 1 1 1 1 1 1 1 1 1 1 1 1 1	Name (Brand) Generic) Von olong Von olong Non zioi II ction taken after Drug withdrawn	an)+ n reaction incr	an (pleas ose eased	No. A4kh rocg e lick) Dose reduced	(If known) I-J-20 Dose t chang medicatic	not lined appl	fot lceble remedies	with therapy of	Date Started 2-12-24 10. Read susp Yes	Data Stopped 12-12-74 clion reappy acted medi	Eared after cated after u	reintrodu reintrodu nase rick) Effect nknown	Assessment uction of Oose (if re- introduced)
Ne, 1 1 1 1 1 1 1 1 1 1 1 1 1	Name (Brand/ Generic) Von olong Von oppose Concomilant me	an)+ n reaction incr	on (pleas ose eased	No. A4kh rocg e lick) Dose reduced	(If known) I-J-20 Dose t chang medicatic	not spi	fot licable remedies D,		Date Started 2-12-24 10. Read susp Yes	Date Stopped 12-12-24 Ition reappiected medi N	Eared after cated after u	Idri reintrodu ase rick) Effect nknown	Assessment uction of Oose (if re- introduced)
No. 1 1 1 1 1 1 1 1 1 1 1 1 1	Name (Brand) Generic) Von olong Von olong Non zioi II ction taken after Drug withdrawn	an)+ n reaction incr	on (pleas ose eased	No. A4kh rocg e lick) Dose reduced	(If known) I-J-20 Dose t chang medicatic	not ppl	fot licable remedies D,	with therapy of Therapy	Date Started 2-12-20 10. Rea susp Yes Sales (Enclu Dates	Date Stopped 12-12-24 Ition reappiected medi N	Eared after cated after u	reintrodu reintrodu nase rick) Effect nknown	Assessment uction of Oose (if re- introduced)
No. 1 H H H S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. A S. S. S. A S. S. S. S. S. S. S. S. S. S.	Name (Brand) Generic) Von olong Von olong Non zioi II ction taken after Drug withdrawn	an)+ n reaction incr	on (pleas ose eased	No. A4kh rocg e lick) Dose reduced	(If known) I-J-20 Dose t chang medicatic	not ppl	fot licable remedies D,	with therapy of Therapy	Date Started 2-12-20 10. Rea susp Yes Sales (Enclu Dates	Date Stopped 12-12-24 Ition reappiected medi N	Eared after cated after u	reintrodu reintrodu nase rick) Effect nknown	Assessment uction of Oose (if re- introduced)
No. 1 1 1 1 1 1 1 1 1 1 1 1 1	Name (Brand) Generic) Von olong Von olong Non zioi II ction taken after Drug withdrawn	a)) 4 (P) Incr Incr Incr Incr Incr	on (pleas ose eased	No. A4kh rocg e lick) Dose reduced	(If known) I-J-20 Dose t chang medicatic	not ppl	sot licable remedies 0, Del	with therapy of Therapy	Date Started S-12-20 10. Reac susp Yes Ves Dates (Exclu Dates Date Sto	Date Stopped 12-12-24 Ition reappiected medi N	Eared after cated after u	reintrodu reintrodu nase rick) Effect nknown	Assessment uction of Oose (if re- introduced)

Handatory Fields for suspected ADR Reporting Form



Email: editor@ijfmr.com



### Prescription Audit for Vonoprazan

- 1. Prescription Detail
  - Patient Name ...Hing...shoith.....
  - Prescriber Name. T.L. Salish. Justed
  - > Date of Prescription......
  - Diagnosis/Indication D Yes D No
- 2. Drug & Dosage Appropriateness
  - Indication Appropriate (GERD, PUD, H.pylori, etc): D-Yes D No
  - > Dose & Strength (10 mg / 20 mg) Appropriate: Yes No
  - Duration Specified & Appropriate: Yes I No
- 2.1. H. pylori Eradication Regimen (if applicable):
  - Vonoprazan + Amoxicillin + Clarithromycin/Metronidazole Correctly Prescribed: 
    Yes 
    No
    - Duration of 7-14 Days Mentioned: Yes No
- 3. Safety & Drug Interactions

>

- Any Contraindications Checked (e.g., Liver Disease, Pregnancy)? 
   Yes 
   No
- Drug Interactions Considered (e.g., CYP3A4 Drugs, Anticoagulants)? Set I No
- ➢ Renal/Liver Function Checked (if necessary)? □ Yes □ No
- Risk of Long-term Use (Osteoporosis, Hypomagnesemia) Considered? Yes No
- 4. Patient Instructions & Adherence
  - > Clear Instructions on Timing with Meals: -Yes No
  - Patient Advised on Possible Side Effects: 
    -Yes 
    No
  - Advised to Complete Full Course (If for H. pylori)? 
    Yes 
    No
- 5. Cost & Accessibility Considerations:
  - > Generic or Cost-effective Brand Considered: 🗆 Yes 🗆 No
  - > Availability Confirmed: Ves D No

Total "Yes" Responses: ..../15

Auditor Name & Date: fritm. filif. fendar (10-3-25)



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

~	11.0		1 1		and the second se			Coordination C nt of India, Sec -3024 (9:00 A	10 5:10				
	THE REAL PROFESSION	( And a lot of		Fe	lion-up Ca	ne 🛛		-3024 (9:00 A		R AMC / N			and so at
	isent Initiaterin			-	-			Reg. No. /				all t	Section 1
	nder MD F.C			2. Age or				AMC Report		1			
			÷ 1	4.Weight (	in ed }	43 E	1	Worldwide	The state is not in the second second				
E.	ent / Reaction 1	LESSE RU	ACTIO		100	-2.5	ALC: N	12. Relevan	it investige	tions with d	ales :		
	rent / Reaction 1	top date	ddim.	in the second second									
D	escribe Event/Re	taction m	inagen	nent with de	tails , if an	iy.	-						
						<i>6</i> 0							
								13. Relevan	t medical (	medication	history fe		
								pregnancy, i	addiction, b	repatic, rena	dysfunction	on etc.)	pes.
								1			Г	٦ r	
											Ľ	Γ.	
								14. Cusr	ints of the	rearline - M		<u> </u>	
								ODeath (dd	(mm/ymy)	reactions . In	and the second se	al-anom	a lick anyone a'y
									tening ation-Initi	Trainconert	DOrsabili DOther N		7
								15. Com			- other P	L	ertant
								GRecovered Of atal	1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	overing		ONot Re	
	USPECTED ME			CIRCUT-		-		Ciratai	LIRect	ivered with	sequelae	Unknow	MC.
i.	8. Name		factu er	Batch No.	Expiry Date	Dose	Route	Frequency		py Dates	Indicat	tion	Causality
	(Brand/ Generic)	(if ke	own)	Lot No.	(If known)				Date Started	Date Stopped		1	Assessment
-	Vanalang		-	AAFAXCO		15 mg	Oral		30-11-24	03-12-24	PUD	-	
	(NED DATES	0.01		_	_	J					1.9.9		
1													
-							1						
*	Action taken afte	r reaction	(pleas	e tick)					10. Read	tion reappe	ared after	reintroduc	tion of
,# 1. /	Action taken after Drug	Dos		Dose	Dose no		Not	Unknown	\$950	tion reappe	ation (pier	ase lick)	
, /	Action taken after Drug withdrawn			144 (16 A)	Dose no change		Not plicable	Unknown	10. Read susp Yes	ction reappe sected medic No	ation (ples	reintroduc ase lick) Effect hknown	Dose (if re-
, / 5. 0.	Action taken after Drug withdrawn	Dos		Dose				Unknown	\$950	sected medic	ation (ples	ase lick) Effect	Dese
," 5. 10. 11	Action taken after Drug withdrawn	Dos		Dose				Unknown	\$950	sected medic	ation (ples	ase lick) Effect	Dose (if re-
, ) 5. 10. 11	Action taken after Drug withdrawn	Dos		Dose				Unknown	\$950	sected medic	ation (ples	ase lick) Effect	Dose (if re-
	Action taken after Drug withdrewn	Dos Increa	e sed	Dose reduced	change	d ap	plicable		Yes	No No	ution (pie:	ase lick) Effect aknown	Dose (if re- Introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomutant me	Dos Increa	e sed	Dose reduced	change medication	and herba	plicable	with therapy d	Yes Yes	No No	ed to treat	ase lick) Effect hknown reaction)	Dose (if re- introduced
y" S. 10. 11 11 111 111	Action taken after Drug withdrawn	Dos Increa	e sed	Dose reduced	change medication	d ap	i remedies		Yes Yes	ide thase us	ed to treat	ase lick) Effect aknown	Dose (if re- introduced
S. 10. 11 11 111 111 111 111 111 111 111	Action taken after Drug withdrawn Concomutant me	Dos Increa	e sed	Dose reduced	change medication	and herba	i remedies	with therapy d Therapy	Yes Yes lates (Exclu Dates	ide thase us	ed to treat	ase lick) Effect hknown reaction)	Dose (if re- introduced
	Action taken after Drug withdrawn Concomutant me	Dos Increa	e sed	Dose reduced	change medication	and herba	i remedies	with therapy d Therapy	Yes Yes lates (Exclu Dates	ide thase us	ed to treat	ase lick) Effect hknown reaction)	Dose (if re- introduced
- ) 5. 0. 7 C 1 11 11 11 11 11 11	Action taken after Drug withdrawn Concomitant me Name b, (Brand / Ger	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies 20, Dat	with therapy d Therapy e Started	turs Yes Jales (Exclu Dates Dates Sto	ide thase us	ed to treat	ase lick) Effect hknown reaction)	Dose (if re- introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomutant me	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies	with therapy d Therapy e Started	tursp Yes lates (Exclu Dates Date Sto	pected medic No ide thase us pped	ation (play	ereaction) Indicatie	Dose (if re- introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomitant me Name b, (Brand / Ger	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies	with therapy of Therapy e Started EPORTER DET	Yes Yes lates (Exclu Dates Date Sto	ected medic Me ide thase us pped	ation (pier	Iffect known reaction Indicatio	Dase (if re- introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomitant me Name b, (Brand / Ger	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies	with therapy d Therapy e Started	AILS	pped	ed to treat	reaction) Indicatio	Dase (if re- introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomitant me Name b, (Brand / Ger	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies	with therapy of Therapy e Started EPORTER DET Name & Addres POJ03h: 445202 ER KI No. : <u>94</u>	Alls A Alls Alls A Alls Alls Alls A Alls Alls Alls Alls A Alls Alls Alls Alls Alls Alls Alls Alls	peed have us afri wito a fill the second sec	ed to treat	iknown iknown reaction) Indicatio	Dase (if re- introduced
· · · · · · · · · · · · · · · · · · ·	Action taken after Drug withdrawn Concomitant me Name b, (Brand / Ger	Dos Increa dical prod	e sed	Dose reduced	change medication	and herba	l remedies 20, Dat 0 R 16. A) Pin : Conta Occu	with therapy of Therapy e Started EPORTER DET Name & Addres polocyh: 445202 EP	Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls Alls A	pped	ed to treat	iknown iknown reaction) Indicatio	Dase (if re- introduced



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

### Prescription Audit for Vonoprazan

#### 1. Prescription Detail

- Prescriber Name.....Shank...mahaal.
- > Date of Prescription.30211-24.
- Diagnosis/Indication 
  Yes 
  No
- 2. Drug & Dosage Appropriateness
  - Indication Appropriate (GERD, PUD, H.pylori, etc): HYes I No
  - Dose & Strength (10 mg / 20 mg) Appropriate: Yes D No
  - > Duration Specified & Appropriate: Yes No
- 2.1. H. pylori Eradication Regimen (if applicable):
  - Vonoprazan + Amoxicillin + Clarithromycin/Metronidazole Correctly Prescribed: 
    Yes 
    No
    - Duration of 7-14 Days Mentioned: -Yes O No
- 3. Safety & Drug Interactions
  - Any Contraindications Checked (e.g., Liver Disease, Pregnancy)? Pres No
  - Drug Interactions Considered (e.g., CYP3A4 Drugs, Anticoagulants)? 
    Pres 
    No
  - Renal/Liver Function Checked (if necessary)? □ Yes □ No
  - Risk of Long-term Use (Osteoporosis, Hypomagnesemia) Considered? I Yes I No
- 4. Patient Instructions & Adherence
  - Clear Instructions on Timing with Meals: TYes I No
  - Patient Advised on Possible Side Effects: 
    Yes 
    No
  - Advised to Complete Full Course (If for H. pylori)? TYes No
- 5. Cost & Accessibility Considerations:
  - Generic or Cost-effective Brand Considered: Ses I No
  - Availability Confirmed: Yes I No

Total "Yes" Responses: .!4./15

For more patient detail here are the link are attached https://drive.google.com/file/d/1gfr5jexsHDuXzEJAJgumizwidZMM1Idj/view

#### 3. Result

### 3.1 clinical trial

Vonoprazan, a potassium-competitive acid blocker (P-CAB), has been extensively evaluated in Phase I– III clinical trials to assess its safety and efficacy in treating acid-related gastrointestinal conditions. Here's a summary of the pharmacovigilance data from these trials:



### Phase III Clinical Trials: Safety Outcomes

### 1. Erosive Esophagitis (EE):

**Study Design:** A Phase III, randomized, double-blind, multicentre study compared vonoprazan 20 mg to lansoprazole 30 mg in Asian patients with EE.

**Results:** At 8 weeks, EE healing rates were 92.4% for vonoprazan and 91.3% for lansoprazole, demonstrating non-inferiority.

**Safety:** Treatment-emergent adverse events (TEAEs) occurred in 38.1% of vonoprazan-treated patients and 36.6% of those on lansoprazole, indicating similar safety profiles.³⁷

#### 2. Gastric and Duodenal Ulcers:

**Study Design:** Randomized clinical trials assessed vonoprazan 20 mg versus lansoprazole 30 mg for healing gastric (GU) and duodenal ulcers (DU).

**Results:** Vonoprazan was non-inferior to lansoprazole in GU healing and had similar efficacy in DU healing.

**Safety:** TEAEs were slightly lower for GU and slightly higher for DU with vonoprazan compared to lansoprazole. One death (subarachnoid hemorrhage) occurred in the vonoprazan group, with the possibility of a relationship to the study drug not ruled out.

#### Long-Term Safety: VISION Trial

Study Design: The VISION trial is a Phase IV, open-label, multicenter study in Japan, evaluating the long-term safety of vonoprazan as maintenance therapy for healed EE over a 5-year period.

#### Interim Results (3-Year Analysis):

Histopathology: Gastric mucosal evaluations showed that hyperplasia of parietal, foveolar, and G cells was more common with vonoprazan than with lansoprazole at week 156. However, no neoplastic changes were observed in either group.

#### regulatory Review and Approval

FDA Review: The U.S. FDA reviewed data from pivotal studies, including Protocol EE-301, which evaluated the efficacy and safety of vonoprazan 20 mg compared to lansoprazole 30 mg for healing EE, and vonoprazan (10 mg and 20 mg) compared to lansoprazole 15 mg for maintenance of healing.³⁸

#### **3.2 Post-marketing surveillance**

Post-marketing surveillance of vonoprazan, a potassium-competitive acid blocker (P-CAB), has provided valuable insights into its safety profile beyond clinical trials. Real-world data have identified both common and rare adverse events (AEs), contributing to a comprehensive understanding of the drug's risk-benefit balance.

#### **Common Adverse Events**

In routine clinical practice, vonoprazan is generally well-tolerated. Commonly reported adverse drug reactions (ADRs) include: Gastrointestinal symptoms: Diarrhea, nausea, dysgeusia (altered taste), soft **stools** 

These ADRs are typically mild and transient. For instance, a post-marketing surveillance study in Japan reported ADR incidences of 3.22% for first-line therapy and 1.89% for second-line therapy in Helicobacter pylori eradication regimens

### Serious and Rare Adverse Events

While serious AEs are uncommon, post-marketing data have identified several rare but noteworthy events: **Hypersensitivity reactions:** Anaphylactic shock, urticaria, drug eruptions

**Hepatic disorders:** Hepatic injury, hepatic failure, jaundice



Severe skin reactions: Erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)³⁹

vonoprazan and proton pump inhibitors (PPIs) from a pharmacovigilance perspective, emphasizing safety outcomes, post-marketing data, and adverse drug reactions (ADRs):

#### 1. Mechanism of Action

Vonoprazan: Potassium-Competitive Acid Blocker (P-CAB) — offers rapid, strong, and sustained acid suppression by competitively inhibiting H+/K+-ATPase.

PPIs (e.g., omeprazole, lansoprazole): Irreversibly bind H+/K+-ATPase — require acid activation and take longer to reach maximal effect.

Clinical Relevance: Faster onset with vonoprazan may contribute to different ADR patterns, especially early in treatment.

#### **3.3 Drug-Drug Interactions**

Vonoprazan: Lower interaction potential with CYP enzymes (mainly CYP3A4).

PPIs: Metabolized mainly via CYP2C19 and CYP3A4; higher interaction risk with drugs like clopidogrel.³⁹

#### 4. Discussion

#### **Interpretation of the Safety Data:**

Clinical trials and post-marketing surveillance suggest that vonoprazan is generally well-tolerated, with an adverse event (AE) profile similar to that of traditional proton pump inhibitors (PPIs). Common AEs include gastrointestinal symptoms (e.g., diarrhea, nausea) and skin reactions, typically mild and self-limiting.

#### **Comparison to Traditional PPIs:**

Vonoprazan offers faster and more potent acid suppression compared to PPIs. Safety data show comparable rates of adverse events, though vonoprazan may be associated with slightly higher rates of dysgeusia and rare gastrointestinal events like hemorrhagic enterocolitis. PPIs have a well-established link to long-term risks (e.g., hypomagnesemia, kidney disease), which are not yet confirmed for vonoprazan.

#### **Limitations in Current Data:**

Long-term safety data are limited, especially outside of Japan.

Most available studies involve short-duration use or specific populations, limiting generalizability.

Real-world data are still emerging, and rare adverse events may be underreported.

### Need for Continued Monitoring:

As vonoprazan use expands globally, ongoing pharmacovigilance and real-world evidence are crucial to detect delayed or rare adverse effects, ensure patient safety, and better define its risk-benefit profile compared to PPIs.

#### Conclusion

The overall safety profile of vonoprazan appears acceptable based on data from Phase I–III clinical trials and early post-marketing surveillance. Adverse events are generally mild and comparable to those seen with traditional proton pump inhibitors (PPIs). While some rare and serious events have been reported—such as hypersensitivity reactions and gastrointestinal complications—these are uncommon and not clearly more frequent than with PPIs.



However, the limited long-term safety data, particularly outside of Japan, highlight the need for continued monitoring. As global use increases, further real-world evidence and post-marketing studies will be essential to fully establish its safety over extended treatment periods.

In summary, vonoprazan represents a promising alternative to PPIs with a favorable short-term safety profile, but long-term vigilance is warranted

### Reference

- Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther
- Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fuorophenyl)-1-(pyridin-3ylsulfonyl)-1H-pyr-rol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011
- 3. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal refux dis-ease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018
- 4. Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, doubleblind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;
- Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y. Efcacy of vonoprazan for 24-week maintenance therapy of patients with healed refux esophagitis refractory to proton pump inhibitors. Biomed Rep.2018
- 6. Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, et al. Efcacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant refux esophagitis. Esophagus.2019
- 7. Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015
- 8. Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efcacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
- 9. Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, et al. Evidence-based clinical practice guidelines for gastroesophageal refux disease 2015. J Gastroenterol.
- 10. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol.
- 11. Morris DL, Watson SA, Durrant LG, Harrison JD. Hormonal control of gastric and colorectal cancer in man.
- 12. Takhar AS, Eremin O, Watson SA. The role of gastrin in colorectal carcinogenesis. Surgeon.
- 13. Takhar AS, Eremin O, Watson SA. The role of gastrin in colorectal carcino genesis. Surgeon.
- 14. M, Tanaka S, Maeda M, Takamura A, Tatsugami M, Wada Y, et al. Role of the gastrin-gastrin receptor system in the expansive growth of human gastric neoplasms. Digestion.



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

- 15. Kinoshita Y, Ishihara S. Mechanism of gastric mucosal proliferation induced by gastrin. J Gastroenterol Hepatol. 2000;15(Suppl):D7-11.
- 16. García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut
- 17. Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511.
- 18. Haruma K, Yoshihara M, Sumii K, Tari A, Watanabe C, Kodoi A, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28(7):633–7.
- 19. Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;
- 20. Ashida K. Notes on features and uses of medications used for PPI- resistant GERD, drugs under development and future prospects.
- 21. Cederberg C, Lind T, Röhss K, Olbe L. Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.
- 22. Peura DA, Riff DS, Snoddy AM, Fennerty MB. Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther 2009
- 23. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003;
- 24. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004
- 25. Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016
- 26. Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med 2011
- 27. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009
- 28. Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol 2009;
- 29. 37. Takahari K, Haruma K, Ohtani H, Kiyoto S, Watanabe A, Kamada T, et al. Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med. 2017
- 30. 40. Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol.
- 31. Abdel-Aziz Y, Metz DC, Howden CW. Review article:potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;
- 32. 6. Keeling DJ, Taylor AG, Schudt C. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine3-acetonitrile, to the gastric (H++K+)-ATPase. J Biol Chem.
- 7. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.



- 34. Drug approval review for vonoprazan fumarate (in Japanese), the pharmaceuticals and medical devices agency of Japan. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther Voquezna. Package insert. Florham Park, NJ: Phathom Pharmaceuticals;
- 35. Hou X, Meng F, Wang J, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
- 36. Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study.
- 37. Hatano Y, Haruma K, Ayaki M, Kamada T, Ohtani H, Murao T, et al. Black spot, a novel gastric fnding potentially induced by proton pump inhibitors. Intern Med Voquezna. Package insert. Florham Park, NJ: Phathom Pharmaceuticals; 2022